The nurse is reviewing the medication orders for a patient who will be receiving aminoglycoside therapy.
Which other medication or medication class, if ordered, would be a potential interaction concern?

Choice A rationale:

Double vision is not a common side effect of quinolones. Quinolones are a type of antibiotic that are used to kill or inhibit the growth of bacteria. While they can have side effects, double vision is not typically one of them.

Choice B rationale:

Tendonitis and tendon rupture are known adverse effects of quinolones. These antibiotics can very rarely cause long-lasting, disabling, and potentially irreversible side effects, sometimes affecting multiple systems, organ classes, and senses. One of these side effects is damage to the tendons, which can manifest as tendonitis (inflammation of the tendon) or even tendon rupture. This is particularly a concern for people older than 60 years and for those with renal impairment or solid-organ transplants because they are at a higher risk of tendon injury.

Choice C rationale:

Neuralgia, or nerve pain, is not a common side effect of quinolones. While these antibiotics can affect the nervous system and cause side effects such as peripheral neuropathy and central nervous system effects, neuralgia is not typically reported.

Choice D rationale:

Hypotension, or low blood pressure, is not typically associated with the use of quinolones. These antibiotics can have various side effects, but a significant drop in blood pressure is not commonly reported.

Choice A rationale:

Zidovudine, also known as AZT, is a medication used for the treatment of human immunodeficiency virus (HIV) infection. One of the major dose-limiting toxic effects of Zidovudine is hematologic toxicity, which manifests clinically as anemia, neutropenia, and sometimes as platelet deficits with onset after several weeks of treatment. This hematologic toxicity is essentially a form of bone marrow suppression. Therefore, bone marrow suppression is the dose-limiting adverse effect of zidovudine therapy.

Choice B rationale:

Retinitis is not a known dose-limiting adverse effect of zidovudine. While zidovudine has a range of side effects, retinitis is not commonly associated with its use.

Choice C rationale:

Renal toxicity is not a known dose-limiting adverse effect of zidovudine. While zidovudine can have various side effects, renal toxicity is not typically one of them.

Choice D rationale:

Hepatotoxicity is not the dose-limiting adverse effect of zidovudine. While severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of zidovudine, it is not considered the dose-limiting adverse effect. The dose-limiting adverse effect is more specifically related to hematologic toxicity, which includes bone marrow suppression.